Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

Tuberculosis Clinical Trial

Official title:

A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01683773
• Other study ID #: TB032
• Status: Completed
• Phase: Phase 1
• First received: August 24, 2012
• Last updated: September 16, 2014
• Start date: September 2012
• Est. completion date: August 2014

Study information

• Verified date: September 2014
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This trial will investigate the administration of two new tuberculosis vaccines, called AERAS-402 and MVA85A. The purpose of this trial is to assess what happens when both of these vaccines are given one after the other. The trial will assess the safety of both vaccines and also their ability to stimulate an immune response within the body. It is hoped that when these two vaccines are given in sequence, the combined immune response is even better than when each vaccine is used individually.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Subjects must meet all of the following criteria to enter the trial:

• Healthy adult aged 18-55 years

• Resident in or near Oxford (for CCVTM) or Birmingham (for WTCRF; and able to travel to Oxford for vaccinations) for the duration of the trial period

• No relevant findings in medical history or on physical examination

• Confirmation of prior vaccination with BCG not less than 6 months prior to projected trial vaccination date (by visible BCG scar on examination or written documentation)

• Allow the Investigators to discuss the individual's medical history with their GP

• Use effective contraception for the duration of the trial period (females only)

• Refrain from blood donation during the trial

• Give written informed consent

• Allow the Investigator to register subject details with a confidential database to prevent concurrent entry into clinical trials

• Agrees to avoid elective surgery for the duration of the trial

• Has a body mass index (BMI) between 18 and 33 (weight/height2) by nomogram

• Able and willing (in the Investigator's opinion) to comply with all the trial requirements

Exclusion Criteria:

Subjects must meet none of the following criteria to enter the trial:

• Laboratory evidence at screening of latent M. tb infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens

• Clinical, radiological, or laboratory evidence of current active TB disease

• Shared a residence within one year prior to day 0 with an individual on anti-tuberculosis treatment or with culture- or smear-positive pulmonary tuberculosis

• Previous treatment for active or latent tuberculosis infection

• Received a TST within 90 days prior to day 0

• Received a systemic antibiotic within 14 days prior to day 0

• Inability to discontinue daily medications other than the following during the trial:

oral contraceptives, vitamins, nonprescription nutritional supplements, aspirin, antihistamines, antihypertensives, antidepressants, inhaled steroids, bronchodilators, and any other stable, regular medication not deemed to have an impact on safety or immunogenicity.

• Previous vaccination with candidate vaccine MVA85A or candidate vaccine FP85A or any other recombinant MVA or adenoviral vaccine; AERAS-402; or any other investigational M. tb vaccine

• Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), autoimmune disease, cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse

• History of serious psychiatric condition

• Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents

• History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, including eggs

• Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the subject in the triala

• Positive HBsAg, HCV or HIV antibodies

• Female currently lactating, confirmed pregnancy or intention to become pregnant during trial period

• Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the trial vaccine for 30 days prior to dosing with the trial vaccine, or planned use during the trial period

• Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date

• Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject's ability to participate in the trial

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• AERAS-402
Intramuscular needle injection 1x10^11 vp
• MVA85A
Intradermal needle injection 1x10^8 pfu

Locations

Country	Name	City	State
United Kingdom	The Wellcome Trust Clinical Research Facility (WTCRF), University of Birmingham	Birmingham	West Midlands
United Kingdom	Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital	Oxford	Oxfordshire

Sponsors (5)

Lead Sponsor	Collaborator
University of Oxford	Aeras, Crucell Holland BV, Emergent BioSolutions, University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of AERAS-402 followed by MVA85A	To evaluate the safety profile of multiple doses of AERAS-402 alone, compared to one and two doses of AERAS-402 followed by MVA85A in healthy, BCG vaccinated adults, measured by number and severity of local and systemic adverse events	3 months after final vaccination	Yes
Secondary	Immunogenicity of AERAS-402 followed by MVA85A	To evaluate and compare the immune responses as described by flow cytometric intracellular cytokine staining, antibody serology, and Elispot assays of multiple doses of AERAS-402 alone, compared to one and two doses of AERAS-402 followed by MVA85A in healthy, BCG vaccinated adults	12-18 months after first vaccination	No

External Links

•   The Jenner Institute - Clinical Trials